Table 1. Clinical trials for patients with adenoid cystic carcinoma by molecular target.
Indicates targets identified in our cohort of 20 patients with adenoid cystic carcinoma.
The trial listed is for gastrointestinal cancers, and evidence for activity of mebendazole against MYB is preclinical.
Abbreviations: BRCA1, breast cancer type 1 susceptibility DNA repair associated; c‐kit, KIT proto‐oncogene receptor tyrosine kinase; CTLA‐4, cytotoxic T‐lymphocyte‐associated antigen 4; FGFR, fibroblast growth factor receptor; HDAC, histone deacetylase; MDM2, proto‐oncogene encoding E3 Ubiquitin Ligase; MSKCC, Memorial Sloan Kettering Cancer Center; MYB, proto‐oncogene/transcription factor; NA, not applicable; NCCN, National Comprehensive Cancer Network; NCI, National Cancer Institute; PD‐1, programmed cell death protein 1; PDGFR, platelet‐derived growth factor receptor; PIK3CA, phosphatidylinositol‐3‐OH kinase; PRMT5, protein arginine methyltransferase 5; RET, proton‐oncogene rearranged during transfection; VEGFR, vascular endothelial growth factor receptor.